Page 90 - Clinical Development News Today

With more than 63 biopharma companies attending and 15 event partners sharing solutions, the 7th Annual IPF Summit being held in Boston next month (September 2023) is not to be missed.

/PRNewswire/ -- The "Global Influenza Vaccines Market, Persons Vaccinated, Key Company Analysis, Emerging Players Profile, Promising Influenza Vaccines in...

With so many advanced therapies on the horizon, the next few years are poised to be one of significant progress for patients with over 2000 cell and gene therapies in active clinical trials globally.

With more than 63 biopharma companies attending and 15 event partners sharing solutions, the 7th annual IPF Summit being held in Boston next month (September 2023) is not to be missed.

The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.

A supplemental biologics license application seeking the expanded approval of amivantamab-vmjw in combination with carboplatin plus pemetrexed for use in the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations has been submitted to the FDA.

In Bangladesh, there’s an immense need for innovative biotechnology-based products for creating new jobs and introducing innovative solutions to problems specific to our country.

FORE Biotherapeutics yesterday (August 23) announced the closing of its $75 million (£59 million) series D financing, led by the SR One and co-led by Medicxi and joined by existing investors.

It is natural for parents to protect their children from any harm, including the endless array of germs they are exposed to every day.

Hutchmed is planning to submit a New Drug Application (NDA) for treatment of primary immune thrombocytopenia (ITP) in China.